Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. What advice do you have for other start-ups hoping to launch into this market? What is unique about your engine?

RNA 52

RNA Engineer Life Science Drugs 52

BioTech 365

JANUARY 14, 2022

RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis / Transcriptomics – Global (..)

RNA 40

RNA Marketing 40

BioTech 365

FEBRUARY 3, 2022

Viral RNA Polymerase Inhibitor Drug Pipeline Market Research Report 2022: Therapeutics Scenario and Growth Prospects Across Viral RNA Polymerase Inhibitor Development – ResearchAndMarkets.com Viral RNA Polymerase Inhibitor Drug Pipeline Market Research Report 2022: Therapeutics Scenario and Growth Prospects Across Viral … Continue reading (..)

RNA 40

RNA Marketing Development Research 40

BioPharma Reporter

APRIL 30, 2024

A recent study finds RNA deals are âdominatedâ by oligonucleotides and mRNA vaccines in APAC

RNA 52

RNA Vaccination Vaccine Regulation 52

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNA delivery and target specificity. Engage in the growing advances and development of RNA tools for vaccines and anti-infectives. London, UK.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

pharmaphorum

JANUARY 19, 2022

The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. Its mission is to introduce and accelerate the adoption of groundbreaking life science research tools to their markets.

RNA 72

RNA Research Life Science Bioinformatics 72

BioTech 365

SEPTEMBER 13, 2021

Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth (..)

RNA 40

RNA Marketing 40

BioTech 365

JUNE 25, 2021

Africa DNA-RNA Sample Preparation Market Report 2021: Prospects, Trends Analysis, Market Size and Forecasts up to 2025 – ResearchAndMarkets.com Africa DNA-RNA Sample Preparation Market Report 2021: Prospects, Trends Analysis, Market Size and Forecasts up to 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … Continue (..)

RNA 40

RNA DNA Marketing 40

BioTech 365

SEPTEMBER 13, 2021

Global RNA Analysis/Transcriptomics … Continue reading →

RNA 40

RNA Marketing 40

BioTech 365

AUGUST 28, 2020

DUBLIN–(BUSINESS WIRE)–The “RNA-interference (RNAi) Market – Growth, Trends, and Forecast (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering. The RNA-interference (RNAi) market is expected to witness a CAGR of 10.12% during the forecast period.

RNA 40

RNA Marketing 40

pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.

RNA 52

RNA Licensing Licensing Development 52

BioTech 365

OCTOBER 7, 2021

Global DNA & RNA Banking Services (Storage Service, Quality Control Service) Market Trends, Analysis & Forecasts Report 2021-2028 – ResearchAndMarkets.com Global DNA & RNA Banking Services (Storage Service, Quality Control Service) Market Trends, Analysis & Forecasts Report 2021-2028 – ResearchAndMarkets.com … (..)

RNA 40

RNA DNA Marketing 40

BioTech 365

FEBRUARY 3, 2022

RNA Interference Drug Pipeline Market Research Report 2022: Insights About 20+ Companies and 20+ Pipeline Drugs in the Pipeline Landscape – ResearchAndMarkets.com RNA Interference Drug Pipeline Market Research Report 2022: Insights About 20+ Companies and 20+ Pipeline Drugs in the … Continue reading →

RNA 40

RNA Marketing Drugs Research 40

BioTech 365

SEPTEMBER 13, 2021

United States RNA Analysis/Transcriptomics Market Research Report 2021 – Forecast to 2026 – Cumulative Impact of COVID-19 – ResearchAndMarkets.com United States RNA Analysis/Transcriptomics Market Research Report 2021 – Forecast to 2026 – Cumulative Impact of COVID-19 – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

RNA 40

RNA Marketing Research 40

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. The company’s VoyageR AI platform integrates computational methods to drug traditionally undruggable RNA targets.

Development 241

Development RNA Gene Therapy Genetics 241

pharmaphorum

MAY 14, 2021

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. It’s not the first partnership for Biogen in the RNA splicing area.

RNA 60

RNA Licensing Licensing Genetics 60

BioPharma Reporter

MARCH 9, 2023

Arranta Bio, a Recipharm company, is doubling capacity at its Massachusetts facility for process development services supporting RNA therapeutics.

RNA 52

RNA Development Regulation Marketing 52

BioTech 365

DECEMBER 10, 2021

Global CRISPR Technology Market Research Report 2021: Focus on Design Tools, Plasmid and Vector, Cas9 and G-RNA, & Delivery System Products – ResearchAndMarkets.com Global CRISPR Technology Market Research Report 2021: Focus on Design Tools, Plasmid and Vector, Cas9 and G-RNA, … Continue reading →

RNA 40

RNA Production Marketing Research 40

World of DTC Marketing

MARCH 16, 2021

IN BRIEF: As a marketer, most of us, like a Jungian archetype, are true Communicators. As a pharma marketer who has worked in many other therapeutic categories and recently on a Covid launch, I have become acutely aware of the interaction between national poles and the on-the-ground sentiment I have observed.

Marketing 180

Marketing Vaccination Vaccine RNA 180

BioTech 365

MAY 7, 2021

Global RNA-based Therapeutics and Vaccines Market Trajectory & Analytics Report 2021: Market to Reach $499 Million by 2027 – Therapeutics to Grow at a CAGR of 68.1% Million – ResearchAndMarkets.com Global RNA-based Therapeutics and Vaccines Market Trajectory … Continue reading →

RNA 40

RNA Marketing Vaccination Vaccine 40

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccination 52

BioTech 365

SEPTEMBER 20, 2021

Global Gene Expression Market Size, Share & Trends Analysis 2021-2028 by Product (DNA Chip/Microarray, Kits & Reagents), Technique (Promoter Analysis, RNA Exp.) – ResearchAndMarkets.com Global Gene Expression Market Size, Share & Trends Analysis 2021-2028 by Product (DNA Chip/Microarray, Kits & … Continue reading → (..)

Gene Expression 40

Gene Expression Reagent DNA RNA 40

Drug Discovery World

FEBRUARY 5, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Gene Therapy 52

Gene Therapy Gene Marketing RNA 52

Roots Analysis

AUGUST 16, 2023

Given such technical and operational challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the contract manufacturing service providers to cater to the urgent global demand.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing RNA 52

pharmaphorum

APRIL 30, 2021

With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce compounds that might alter the course of a disease. The post Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast appeared first on.

RNA 52

RNA Vaccination Vaccine Drugs 52

BioTech 365

MARCH 23, 2021

RSLV-132 by Resolve Therapeutics: A Novel RNase-Fc Fusion Protein Designed to Remove RNA – Global Emerging Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com RSLV-132 by Resolve Therapeutics: A Novel RNase-Fc Fusion Protein Designed to Remove RNA – Global Emerging Insight … Continue reading →

RNA 40

RNA Protein Marketing 40

Drug Discovery World

FEBRUARY 13, 2024

In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Gene Therapy 52

Gene Therapy Gene Marketing RNA 52

Pharmaceutical Technology

AUGUST 1, 2022

In March, the company entered a licensing agreement with Serum Institute of India (SII) to expedite access to messenger RNA products in emerging markets worldwide. In November last year, GreenLight and Samsung Biologics entered a collaboration agreement to manufacture mRNA Covid-19 vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

MARCH 28, 2023

lower than the previous market day’s close. There is much interest in the industry around RNA-based therapeutics as their utilisation in indications beyond Covid-19 come into focus. Covid-19 vaccine-related revenue is predicted to drop from an estimated $17.1bn in 2022 to $5bn in 2023.

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Roots Analysis

FEBRUARY 21, 2022

These kits require less input sample, produce sufficient DNA / RNA libraries with minimum errors and are compatible with a broad range of input samples, including blood, cells, plasma and saliva. The various advantages of NGS are briefly described below: Next Generation Sequencing (NGS) Library Preparation Kits Market – Roots Analysis.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The market for mRNA-based vaccines and therapeutics is projected to grow from $46.7 RNA technology is not new nor has its potential been surprising.

Life Science 98

Life Science RNA Vaccination Vaccine 98

Pharma Mirror

FEBRUARY 2, 2022

Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.

RNA 130

RNA Manufacturing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

OCTOBER 5, 2022

miRecule and Sanofi have entered a strategic partnership and exclusive licence agreement for the development and commercialisation of an antibody-RNA conjugate (ARC) to treat facioscapulohumeral muscular dystrophy (FSHD). The anti-DUX4 RNA therapy was discovered using the DREAmiR platform of miRecule.

Development 130

Development RNA Gene Therapy Sales 130

BioPharma Reporter

JULY 10, 2023

Contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro, to form a new strategic commercial alliance.

RNA 52

RNA Manufacturing Development Regulation 52

BioSpace

OCTOBER 7, 2020

The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology. 10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology.

Genome 65

Genome Genomics RNA Marketing 65

BioPharma Reporter

JANUARY 23, 2023

Charles River Laboratories International, Inc and Rznomics Inc, a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have established a viral vector contract development and manufacturing organization (CDMO) partnership.

Gene 111

Gene Gene Therapy Development RNA 111